Lparomlimab & Tuvonralimab Injection Qibeian is a bi-functional monoclonal antibody combination (PD‑1/CTLA‑4) developed by Qilu Pharmaceutical (QL1706), supplied as 50 mg in 2 mL vials. Approved by China’s NMPA (conditional marketing authorization No. S20240044; drug code 86904021005238). Intended exclusively for lab and investigative research applications, not for clinical or human use.